These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30346627)

  • 1. Impact of Brexit on UK and EU Drug Regulation and Patient Access.
    Breckenridge A; Feldschreiber P
    Clin Pharmacol Ther; 2019 Apr; 105(4):923-925. PubMed ID: 30346627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
    Jackson EL; Feldschreiber P; Breckenridge A
    Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
    Danieli D
    Health Econ Policy Law; 2021 Jan; 16(1):64-75. PubMed ID: 32434612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The consequences of 'Brexit' for drug discovery and development, and the regulatory implications.
    Golding BT; Waring MJ
    Expert Opin Drug Discov; 2018 Jul; 13(7):583-585. PubMed ID: 29634365
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union.
    Wright JSF; Doukas D
    Health Econ Policy Law; 2021 Jul; 16(3):256-272. PubMed ID: 32583755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EU launches measures to stop diversion of cut-price drugs.
    Fleck F
    Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
    [No Abstract]   [Full Text] [Related]  

  • 9. Brexit - Consequences for the UK's Oral Health Workforce?
    Eaton KA
    Community Dent Health; 2020 Feb; 37(1):3-4. PubMed ID: 32112675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical price regulation in the UK.
    Lockhart-Mirams A
    Internist (Berl); 2000 May; 41(5):M111-4. PubMed ID: 10917766
    [No Abstract]   [Full Text] [Related]  

  • 11. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engaging with change: Information and communication technology professionals' perspectives on change at the mid-point in the UK/EU Brexit process.
    Lomas E; McLeod J
    PLoS One; 2020; 15(1):e0227089. PubMed ID: 31905215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights.
    Hofer MP; Criscuolo P; Shah N; Ter Wal ALJ; Barlow J
    Front Med (Lausanne); 2022; 9():1011082. PubMed ID: 36590956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How will Brexit affect health and health services in the UK? Evaluating three possible scenarios.
    Fahy N; Hervey T; Greer S; Jarman H; Stuckler D; Galsworthy M; McKee M
    Lancet; 2017 Nov; 390(10107):2110-2118. PubMed ID: 28965715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexit and Animal Protection: Legal and Political Context and a Framework to Assess Impacts on Animal Welfare.
    McCulloch SP
    Animals (Basel); 2018 Nov; 8(11):. PubMed ID: 30453693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.
    Glynn D
    Pharmacoeconomics; 2000; 18 Suppl 1():59-67. PubMed ID: 11151310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waiving the rules.
    Taylor D
    Health Serv J; 1992 Jun; 102(5305):20-2. PubMed ID: 10171042
    [No Abstract]   [Full Text] [Related]  

  • 20. Overview of the European regulatory approval system.
    Pignatti F; Boone H; Moulon I
    J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.